An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer
International Journal of Cancer, 06/27/2012
Tsuji T et al. – The authors established a novel armed oncolytic herpes simplex viruses (HSVs), T–Thrombospondin–1 (TSP–1)–1, which enhanced the antitumor efficacy by providing a combination of direct viral oncolysis with antiangiogenesis. Arming oncolytic HSVs may be a useful therapeutic strategy for gastric cancer therapy.